Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis

OBJECTIVE: To assess whether secukinumab treatment in patients with active psoriatic arthritis (PsA) is associated with sustained inhibition of radiographic progression. METHODS: In this phase III, double‐blind, placebo‐controlled study, 606 patients with PsA were randomized to receive intravenous (...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heijde, Désirée, Landewé, Robert B., Mease, Philip J., McInnes, Iain B., Conaghan, Philip G., Pricop, Luminita, Ligozio, Greg, Richards, Hanno B., Mpofu, Shephard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129532/
https://www.ncbi.nlm.nih.gov/pubmed/27014997
http://dx.doi.org/10.1002/art.39685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129532/
https://www.ncbi.nlm.nih.gov/pubmed/27014997
http://dx.doi.org/10.1002/art.39685

Ejemplares similares